ENLV Overview

Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.

Wall Street analysts forecast ENLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENLV is13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Enlivex Ltd revenue for the last quarter amounts to 0.00 USD, decreased

Enlivex Ltd. EPS for the last quarter amounts to 10.16 USD, decreased -4517.39

Enlivex Ltd (ENLV) has 34 emplpoyees as of May 14 2026.

Today ENLV has the market capitalization of 180.62M USD.